skip to main content

Sign out
Sign in

Language:

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

The American heart journal, 2024-01, Vol.267, p.1-11 [Peer Reviewed Journal]

2023 ;Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. ;2023. The Authors ;ISSN: 0002-8703 ;EISSN: 1097-6744 ;DOI: 10.1016/j.ahj.2023.09.007 ;PMID: 37758044

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics
Author: Nicholls, Stephen J ; Bhatt, Deepak L ; Buse, John B ; Prato, Stefano Del ; Kahn, Steven E ; Lincoff, A Michael ; McGuire, Darren K ; Nauck, Michael A ; Nissen, Steven E ; Sattar, Naveed ; Zinman, Bernard ; Zoungas, Sophia ; Basile, Jan ; Bartee, Amy ; Miller, Debra ; Nishiyama, Hiroshi ; Pavo, Imre ; Weerakkody, Govinda ; Wiese, Russell J ; D'Alessio, David
Subjects: Active control ; Agonists ; Antidiabetics ; Arteriosclerosis ; Atherosclerosis ; Atherosclerosis - complications ; Atherosclerosis - drug therapy ; Blood pressure ; Body mass ; Body mass index ; Body size ; Body weight ; cardiovascular ; Cardiovascular diseases ; Cardiovascular Diseases - drug therapy ; Cerebral infarction ; Clinical significance ; Clinical trials ; Confidence limits ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Double-Blind Method ; Effectiveness ; GIP/GLP-1 receptor agonist ; Glucagon ; Glucagon-Like Peptide-1 Receptor - agonists ; Glucose ; Glycated Hemoglobin ; Heart attacks ; Heart diseases ; high cardiovascular risk ; Humans ; Hypoglycemic Agents ; Liver diseases ; Middle Aged ; Myocardial infarction ; Myocardial Infarction - drug therapy ; Pancreatitis ; Receptors ; Safety ; Stroke - chemically induced ; SURPASS-CVOT ; Thyroid cancer ; tirzepatide ; Treatment Outcome ; type 2 diabetes mellitus ; Vascular diseases
Is Part Of: The American heart journal, 2024-01, Vol.267, p.1-11
Description: Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy of tirzepatide have not been definitively assessed in a cardiovascular outcomes trial. Tirzepatide is being studied in a randomized, double-blind, active-controlled CV outcomes trial. People with type 2 diabetes aged ≥40 years, with established atherosclerotic CV disease, HbA1c ≥7% to ≤10.5%, and body mass index ≥25 kg/m2 were randomized 1:1 to once weekly subcutaneous injection of either tirzepatide up to 15 mg or dulaglutide 1.5 mg. The primary outcome is time to first occurrence of any major adverse cardiovascular event (MACE), defined as CV death, myocardial infarction, or stroke. The trial is event-driven and planned to continue until ≥1,615 participants experience an adjudication-confirmed component of MACE. The primary analysis is non-inferiority for time to first MACE of tirzepatide versus dulaglutide by demonstrating an upper confidence limit <1.05, which will also confirm superiority versus a putative placebo, and also to determine whether tirzepatide produces a greater CV benefit than dulaglutide (superiority analysis). Over 2 years, 13,299 people at 640 sites in 30 countries across all world regions were randomized. The mean age of randomized participants at baseline was 64.1 years, diabetes duration 14.7 years, HbA1c 8.4%, and BMI 32.6 kg/m2. Overall, 65.0% had coronary disease, of whom 47.3% reported prior myocardial infarction and 57.4% had prior coronary revascularization. 19.1% of participants had prior stroke and 25.3% had peripheral artery disease. The trial is fully recruited and ongoing. SURPASS-CVOT will provide definitive evidence as to the CV safety and efficacy of tirzepatide as compared with dulaglutide, a GLP-1 receptor agonist with established CV benefit.
Publisher: United States: Elsevier Inc
Language: English
Identifier: ISSN: 0002-8703
EISSN: 1097-6744
DOI: 10.1016/j.ahj.2023.09.007
PMID: 37758044
Source: MEDLINE
ProQuest Central

Back to results list


	INSPIRE LIBRARY - TON DUC THANG UNIVERSITY		(84-028) 37 755 057	Feedback
	19 Nguyen Huu Tho St. Dist.7, HCM		thuvien@tdtu.edu.vn	Feedback

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait

Searching for
inscope:(TDTS),scope:(SFX),scope:(TDT),scope:(SEN),primo_central_multiple_fe
Show me what you have so far